Posted by Michael Wonder on 12 Dec 2025
PTC Therapeutics announces Health Canada approval of Sephience (sepiapterin) for the treatment of children and adults living with phenylketonuria
10 December 2025 - PTC Therapeutics Canada announced that Health Canada has approved Sephience (sepiapterin) for the treatment of children and adults living with phenylketonuria.
The approval includes broad labeling for the treatment of hyperphenylalaninemia in adult and paediatric patients 1 month old and older with sepiapterin-responsive phenylketonuria.
